advanced hematological malignancy
Conditions
Interventions
=), previous ASCT, organ dysfunction, or active infection will receive regimen 2-1 or 2-2. The other patients will receive regimen 1. Regimen 1 Cyclophosphamide 60mg/kg/day iv. for 2 days TBI
Sponsors
Division of Hematology, Saitama Medical Center, Jichi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria 1.Patients who do not have an available HLA-matched or one locus-mismatched related donor. 2.Patients who have a two- or three-locus-mismatched haploidentical related donor in good condition. (This donor should precede an HLA-matched or one locus-mismatched related donor accoridng to the disease status.) 3.Patients who do not have an HLA-matched or one allele-mismatched unrelated donor, or patients whose disease status preclude time-consuming donor coordination. 4.Patients with high-risk acute leukemia, advanced CML, refractory malignant lymphoma, advanced MDS, acute or lymphoma type ATLL, or refractory severe aplastic anemia. 5.Patients who are 20 to 65 years old 6.Patients in performance status of 0 or 1. 7.Patients whose major organ functions are preserved.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1.Patients with poorly controlled active infection. 2.Patients with coexistence of malignancy. 3.Patients who are pregnant or nursing. 4.Patients with serious mental disorder. 5.Patients with HIV antibody positive. 6.Patients who are allergic to drugs used in conditioning regimen or GVHD prophylaxis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate at 60 days after transplantation with the engraftment of donor cells and without grade III-IV GVHD | — |
Countries
Japan
Contacts
Public ContactShinichi Kako
Saitama Medical Center, Jichi Medical University Division of Hematology
Outcome results
None listed